SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma reported positive subgroup data from the ApproaCH trial…

Ascendis Pharma · PRESS-RELEASE filed May 6, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 6, 2026 at 16:01 ET

Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia. Children ≥5 years showed significantly greater annualized growth velocity vs placebo at Week 52 (+1.78 cm/year, p<0.0001) with sustained improvements through Week 104. The drug was already FDA-approved in February 2026; the data strengthens the profile and supports ongoing EU regulatory review.

  • Subgroup of children ≥5 years at enrollment: AGV treatment difference +1.78 cm/year vs placebo at Week 52 (p<0.0001)
  • Sustained growth improvements observed through Week 104
  • Safety profile consistent with overall population; no symptomatic hypotension or bone age acceleration
  • TransCon CNP (YUVIWEL) FDA-approved February 2026 for achondroplasia in patients ≥2 years

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access